| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Cynthia McLaughlin
Cynthia McLaughlin
Rosalio Madrigal
Cynthia McLaughlin
Cynthia McLaughlin
| Share Statistics | BBOT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $224.5 | $232.8 | 29% |
|
| Shares Out (Mil) | 80.1 | 53.4 | 58% |
|
| Institutional Ownership | 100.0% | 92.9% | 99% |
|
| Float (Mil) | 35.8 | 41.2 | 39% |
|
| Beta | 0.39 | 0.96 | 22% |
|
| Avg Daily Volume (000s) | 737 | 490 | 65% |
|
| Price Change (52-week) |
(75.2%) | 48.2% | 10% |
|
| Growth | BBOT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 10 | 11 | 10 | |
| Current EPS | ($0.662) | ($2.856) | ($2.757) | |
| Month Ago EPS | ($0.659) | ($2.845) | ($2.716) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.561) | ($2.213) | ($2.106) | |
| Year/Year Chg | (6.1%) | (33.6%) | (44.4%) | |
| Financials | BBOT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($182) | ($44) | 7% |
|
| EPS (TTM) | ($2.559) | ($1.600) | 13% |
|
| Operating Cash Flow (TTM) (Mil) | ($151) | ($33) | 4% |
|
| Net Cash Flow (TTM) (Mil) | $23 | $2 | 63% |
|
| Long-Term Debt (Q1) (Mil) | $2 | $4 | 20% |
|
| Enterprise Value (Q1) (Mil) | $55 | $174 | 17% |
|
| Valuation | BBOT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.69 | 2.22 | 15% |
|
| P/E | na | 20.8 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | BBOT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (75.3%) | na |
|
| ROA | (69.0%) | (47.3%) | 9% |
|
| ROE | (381.9%) | (53.3%) | 2% |
|
| Liabilities to Assets | 14.2% | 29.4% | 9% |
|
| F-Score | 1 | 2 | na |
|
BridgeBio Oncology Therapeutics, Inc. did not pass any screens on 10/28/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors
